[
    {
        "outcome_uid": "b21f52d2",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "SSZ",
        "outcome": "Disease activity (follow up: 1 year; assessed with: DAS28-ESR (Lower values \u2013 > benefit) (MCID -1.17)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "fd4777bd",
            "d7a31839"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": "I2= 41%"
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "104",
                    "SSZ": "102"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.14 higher (0.18 lower to 0.47 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "3cdcf796",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "SSZ",
        "outcome": "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values \u2013 > benefit) (MCID -0.22)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "fd4777bd",
            "d7a31839"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "104",
                    "SSZ": "102"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.04 lower (0.2 lower to 0.13 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "77864ca9",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "SSZ",
        "outcome": "Pain (follow up: 1 year; assessed with: VAS 0-100 (Lower values \u2013 > benefit) (MCID -11.9)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "d7a31839"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "35",
                    "SSZ": "34"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.1 higher (13.46 lower to 13.66 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "7319701a",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "SSZ",
        "outcome": "Serious adverse events (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "d7a31839"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "0/35 (0.0%)",
                    "SSZ": "3/34 (8.8%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.14 (0.01 to 2.59)",
                    "Absolute Effect (95% CI)": "76 fewer per 1,000 (from 87 fewer to 140 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "617efe0d",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "SSZ",
        "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "fd4777bd",
            "d7a31839"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size and low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "5/104 (4.8%)",
                    "SSZ": "10/102 (9.8%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.51 (0.19 to 1.39)",
                    "Absolute Effect (95% CI)": "48 fewer per 1,000 (from 79 fewer to 38 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "6e817020",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "SSZ",
        "outcome": "Withdrawal due to adverse events (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "fd4777bd",
            "d7a31839"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight"
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": "I2= 44% "
                },
                "Indirectness": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive."
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "MTX monotherapy": "9/104 (8.7%)",
                    "SSZ": "19/102 (18.6%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.46 (0.22 to 0.98)",
                    "Absolute Effect (95% CI)": "101 fewer per 1,000 (from 145 fewer to 4 fewer)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    }
]